Liver transplantation using donor organs with markedly elevated liver enzymes: How far can we go?

Liver International

Volumn 31, Issue 7, 2011, Pages 1021-1027

  Radunz, Sonia ^a   Paul, Andreas ^a   Nowak, Knut ^a   Treckmann, Jürgen W ^a   Saner, Fuat H ^a   Mathé, Zoltan ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Elevated liver enzymes; Extended criteria donors; Liver transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HYDROCORTISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; KIDNEY POLYCYSTIC DISEASE; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER POLYCYSTIC DISEASE; LIVER TRANSPLANTATION; MALE; ORGAN DONOR; PNEUMOCYSTIS PNEUMONIA; PRESCHOOL CHILD; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; END STAGE LIVER DISEASE; HUMANS; LIVER; LIVER TRANSPLANTATION; TISSUE DONORS; TRANSPLANTS; TREATMENT OUTCOME;

EID: 79960105475     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02525.x     Document Type: Article

References (25)

1. Montalti R, Nardo B, Bertelli R, et al. Donor pool expansion in liver transplantation. Transplant Proc 2004; 36: 520-2.
2. Sotiropoulos GC, Lang H, Saner FH, et al. Long-term results after liver transplantation with "livers that nobody wants" within Eurotransplant: a center's experience. Transplant Proc 2008; 40: 3196-7.
3. Sotiropoulos GC, Lang H, Sgourakis G, et al. Liberal policy in living donor liver transplantation for hepatocellular carcinoma: lessons learned. Dig Dis Sci 2009; 54: 377-84.
4. Tector AJ, Mangus RS, Chestovich P, et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg 2006; 244: 439-50.
5. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003; 9: 651-63.
6. Bundes ä rztekammer. Policies regarding solid organ transplantation pursuant to article 16 TPG. Deutsches Ärzteblatt 2004; Heft 5: 246-7.
7. Durand F, Renz JF, Alkofer B, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl 2008; 14: 1694-707.
8. Kniepeiss D, Iberer F, Grasser B, et al. A single-center experience with retrograde reperfusion in liver transplantation. Transpl Int 2003; 16: 730-5.
9. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-90.
10. Radunz S, Hertel S, Schmid KW, et al. Attitude of health care professionals to organ donation: two surveys among the staff of a German university hospital. Transplant Proc 2010; 42: 126-9.
11. Yasutomi M, McCall J, Munn S, Sosef M, Crawford M. In situ split liver transplantation using a donor with a recent history of HELLP syndrome. Transplantation 2006; 81: 639-40.
12. Moussavian MR, Kollmar O, Richter S, Igna D, Schilling MK. Liver transplantation of a HELLP syndrome donor liver in acute fulminant hepatitis B with deltavirus coinfection. Transpl Int 2006; 19: 1030-1.
13. Briceno PJ, Ortiz JA, Manzarbeitia C, et al. Liver transplantation using an organ donor with HELLP syndrome. Transplantation 2004; 77: 137-9.
14. Baron PW, Ojogho ON, Chick W, Concepcion W. Successful liver transplantation using a HELLP syndrome donor. Transplantation 2004; 78: 782-3.
15. Nardo B, Montalti R, Beltempo P, Bertelli R, Cavallari A. Successful liver transplantation from an eclamptic donor complicated by the HELLP syndrome. Transplantation 2003; 76: 440-1.
16. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
17. Axelrod DA, Schnitzler M, Salvalaggio PR, Swindle J, Abecassis MM. The economic impact of the utilization of liver allografts with high donor risk index. Am J Transplant 2007; 7: 990-7.
18. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419-25.
19. Amin MG, Wolf MP, TenBrook JA Jr, et al. Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: a decision analysis. Liver Transpl 2004; 10: 1468-75.
20. Maluf DG, Edwards EB, Kauffman HM. Utilization of extended donor criteria liver allograft: is the elevated risk of failure independent of the model for end-stage liver disease score of the recipient? Transplantation 2006; 82: 1653-7.
21. Briceno J, Marchal T, Padillo J, Solorzano G, Pera C. Influence of marginal donors on liver preservation injury. Transplantation 2002; 74: 522-6.
22. Amersi F, Farmer DG, Shaw GD, et al. P-selectin glycoprotein ligand-1 (rPSGL-Ig)-mediated blockade of CD62 selectin molecules protects rat steatotic liver grafts from ischemia/reperfusion injury. Am J Transplant 2002; 2: 600-8.
23. Pratschke J, Kofla G, Wilhelm M, et al. Improvements in early behaviour of kidney allografts after donor treatment. Transplant Proc 2002; 34: 2213-4.
24. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27: 723-32.
25. McCormack L, Petrowsky H, Jochum W, et al. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 2007; 246: 940-6; discussion 946-8.